Legal Proceedings
−Removed: In the second, third and fourth quarters of 2021 and the first quarter of 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co.
+Added: In the second, third and fourth quarters of 2021 and the first and second quarters of 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co.
Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc.
1 unchanged sentence
These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer’s manufacture, use or sale of the medicine for which the ANDA was submitted.
−Removed: We filed suit in the United States District Court for the District of Delaware in July, August and October 2021 and January 2022, against (i) Teva Pharmaceuticals, Inc.
+Added: We filed suit in the United States District Court for the District of Delaware in July, August and October 2021 and January, May and July 2022, against (i) Teva Pharmaceuticals, Inc.
and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc.
10 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.